Recombinant Cynomolgus/Rhesus VSIG8 Fc Chimera Protein, CF

Measured by its ability to inhibit anti-CD3 antibody induced IFN-gamma secretion by human T cells. The ED50 for this effect 0.500-10.0 μg/mL.

2 μg/lane of Recombinant Cynomolgus Monkey/Rhesus Macaque VSIG8 Fc Chimera Protein (Catalog # 11172-VS) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 56-63 kDa and 110-130 kDa, respectively.

• Reactivity: Pm-Cm, RM
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus/Rhesus VSIG8 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit anti-CD3 antibody induced IL-2 or IFN-gamma secretion by human T cells. The ED₅₀ for this effect 0.500-10.0 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived VSIG8 protein
  

  Cynomolgus Monkey/Rhesus Macaque VSIG8 (Val24-Gly265) Accession # XP_028702448.1	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: XP_028702448.1
• N-terminal Sequence: Val24
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 54 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 56-63 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus/Rhesus VSIG8 Fc Chimera Protein, CF

• V-set and immunoglobulin domain containing 8
• VSIG8

Background

VSIG8 (V-set and immunoglobulin domain containing 8), also known as C1orf204, is an approximately 45 kDa type I transmembrane protein of the B7 family within the Ig superfamily. Based on its similarity with human VSIG8, cynomolgus VSIG8 is predicted to consist of a 242 amino acid (aa) extracellular domain (ECD) containing two V-type Ig-like domains, a 21 aa transmembrane domain, and a 130 aa cytoplasmic domain. Within the ECD, cynomolgus VSIG8 shares 99% and 100% aa identity with human and rhesus VSIG8, respectively.  VSIG8 was identified from proteomic analysis of human hair shafts (1, 2). It is expressed in the hair follicle and shaft, superficial layers of the nail matrix, and superficial layers of oral epithelium (3). R&D Systems in-house testing indicates that VSIG8 inhibits the production of IL-2 by activated T cells.

1. Rice, R.H. et al. (2010) J. Proteome Res. 9:6752.
2. Lee, Y.J. et al. (2006) Mol. Cell. Proteomics 5:789.
3. Rice, R.H. et al. (2011) J. Invest. Dermatol. 131:1936.

Bioinformatics

• Uniprot:
  • XP_028702448.1()